India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,202 Manish Doshi & Family ₹2,000 Cr
Revenue · FY 2025
₹993.72 Cr
▲ 21% YoY
Net profit · FY 2025
₹58.26 Cr
Net margin 5.9%
EBITDA · FY 2025
₹157.18 Cr
EBITDA margin 15.8%
Authorised capital
₹17.5 Cr
Registered with MCA
Paid-up capital
₹3.6 Cr
Issued & subscribed
Open charges
₹531.86 Cr
Satisfied ₹188.81 Cr
Company age
44 yrs
Est. 1982
Employees · EPFO
869
Provident fund records
About Umedica Laboratories Private Limited
Data last updated:
Umedica Laboratories Private Limited is a private limited company based in Pardi, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 05 January 1982 and has been in existence for over 44 years.
Its director Manish Doshi and Family is #1,202 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24231GJ1982PTC141202. Its GSTIN is 24AAACU2966Q1ZS (Gujarat). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹17.5 Cr and a paid-up capital of ₹3.6 Cr. It was formerly known as Umedica Laboratories Limited. It is led by directors including Manish Umed Doshi (Managing Director) and Rupesh Suryakant Kamdar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Pardi, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹993.72 Cr, a growth of 21% compared to the previous year. For the same year it recorded a net profit of ₹58.26 Cr (net margin 5.9%) and EBITDA of ₹157.18 Cr (EBITDA margin 15.8%). Revenue has grown at a compounded annual rate (CAGR) of 77% over three years and 56% over five years.
The company has about 869 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Umedica. As per MCA filings, the company has open charges of ₹531.86 Cr and satisfied charges of ₹188.81 Cr on record. Court records list 99 cases involving the company, including 11 filed by the company and 88 filed against it; 7 cases are pending. The company has 8 deals on record (4 funding rounds, 4 secondary share transfers), with disclosed funding of ₹56.01 Cr; the latest was in October 2022. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Troikaa Pharmaceuticals Limited with revenue of ₹1,088.44 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2024, listing 194 overdue payments to 44 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website umedicalabs.com.
Company details
CIN U24231GJ1982PTC141202
Registration Number 141202
Incorporation Date 05 January 1982
ROC Ahmedabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
CIN history
Umedica Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231GJ1982PTC141202, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231GJ1982PTC141202 | Current |
| U24231MH1982PTC224236 | Previous |
| U24231GJ1982PTC004950 | Previous |
Key People
Manish Umed Doshi Managing Director Rupesh Suryakant Kamdar Director Vandana Manish Doshi Director Recognitions & Rankings of Umedica Laboratories
Contact details
Umedica Laboratories Private Limited's registered office is in Pardi, Gujarat. Its website is umedicalabs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressP. No – 221 222/1 GIDC, Vapi, Pardi, Gujarat, India – 396191
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Umedica Laboratories Private Limited, buy the company report.
Comprehensive company report
Umedica Laboratories Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Umedica Laboratories operates one associated brand: UMEDICA. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations manufacturing and exporting from India. | umedicalabs.com |
Business activity
The main business activity of Umedica Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Umedica Laboratories Private Limited, buy the company report.
Financials of Umedica Laboratories Private Limited
FY 2024 filings availableUmedica Laboratories Private Limited reported revenue of ₹993.72 Cr (up 21% YoY) for FY 2025.
Revenue · FY 2025
₹993.72 Cr ▲ 21%
Net profit · FY 2025
₹58.26 Cr margin 5.9%
EBITDA · FY 2025
₹157.18 Cr margin 15.8%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 21%
3 years · compounded
▲ 77%
5 years · compounded
▲ 56%
EBITDA CAGR growth
1 year
▲ 48%
3 years · compounded
▲ 385%
5 years · compounded
▲ 73%
Revenue has grown at a compounded annual rate (CAGR) of 56% over five years, including 21% growth in the latest year. EBITDA rose 48% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹157.18 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹58.26 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 15.8% | ||||
| Net Profit Margin | 5.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Umedica Laboratories Private Limited, buy the company report.
Board of directors of Umedica Laboratories Private Limited
Umedica Laboratories has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manish Umed Doshi Also directs: Amoli Organics LLP, Umedica Consultancy LLP, Vishwaas Estate Developers LLP and 5 more | Managing Director | 05 Jan 1982 | 44 Years 9 Months | Current |
| Rupesh Suryakant Kamdar | Director | 02 Aug 2018 | 8 Years 2 Months | Current |
| Vandana Manish Doshi Also directs: Amoli Organics LLP, Umedica Consultancy LLP, Ainos Pharmaceuticals Private Limited and 5 more | Director | 17 Mar 2017 | 9 Years 7 Months | Current |
Peer comparison
Umedica Laboratories Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Troikaa Pharmaceuticals Limited | ₹1,088.44 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| Tenshi Pharmaceuticals Private Limited | ₹1,071.06 Cr (FY 2024) | 98.0% | Bangalore, Karnataka, India | |||
| Blue Cross Laboratories Private Limited | ₹1,021.41 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Win-Medicare Private Limited | ₹1,012.12 Cr (FY 2025) | 7.0% | New Delhi, Delhi, India | |||
| Umedica Laboratories Private Limitedthis company | ₹993.72 Cr (FY 2025) | ₹58.26 Cr | 5.9% | 21.0% | 869 | Pardi, Gujarat, India |
| Franco-Indian Pharmaceuticals Private Limited | ₹988.53 Cr (FY 2024) | 0.0% | Mumbai, Maharashtra, India | |||
| Meyer Organics Private Limited | ₹984.18 Cr (FY 2025) | 12.0% | Thane, Maharashtra, India | |||
| Biocon Pharma Limited | ₹982.5 Cr (FY 2025) | 11.0% | Bangalore, Karnataka, India | |||
| Orchid Pharma Limited | ₹949.4 Cr (FY 2025) | 12.0% | Chengalpattu, Tamil Nadu, India | |||
| Fresenius Kabi India Private Limited | ₹934 Cr (FY 2025) | 10.0% | Ranjangaon, Maharashtra, India |
To see the full peer comparison of Umedica Laboratories Private Limited, buy the company report.
Auditor
Umedica Laboratories Private Limited is audited by CNK & Associates LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| CNK & Associates LLP | FY 2024 | 101961W/W-100036 |
Shareholding
The shareholding of Umedica Laboratories Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Umedica Laboratories Private Limited, buy the company report.
Charges & borrowings
Open charges
₹531.86 Cr
Satisfied charges
₹188.81 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Jun 2022 | 100595703 | Hdfc Bank Limited | ₹15 Cr | Open | |
| 10 Feb 2022 | 100543511 | State Bank of India | ₹30 Cr | Open | |
| 01 Nov 2021 | 100503919 | Sbicap Trustee Company Limited | ₹77.89 Cr | Open | |
| 28 Oct 2021 | 100496986 | Sbicap Trustee Company Limited | ₹216.58 Cr | Open | |
| 28 Oct 2021 | 100497172 | Sbicap Trustee Company Limited | ₹132.69 Cr | Open |
To see the full charge records of Umedica Laboratories Private Limited, buy the company report.
Total charge records: 27 View all charges
Deals & funding
Umedica Laboratories Private Limited has 8 deals on record (4 funding rounds, 4 secondary share transfers), with disclosed funding of ₹56.01 Cr; the latest was in October 2022.
Total deals
8
Funding rounds
4
Secondary share transfers
4
Disclosed funding
₹56.01 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2022 | Funding round | ₹99.9 Lakh | Investors: Amoli Organics Private Limited |
| Oct 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2022 | Funding round | ₹32.99 Cr | Investors: Amoli Organics Private Limited , an individual |
| Dec 2020 | Funding round | ₹20 Cr | Investors: 2 individuals |
| Oct 2019 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Umedica Laboratories Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Umedica Laboratories Private Limited has 99 court cases on record: 11 filed by Umedica Laboratories, 88 filed against it. 7 cases are pending and 92 are disposed.
Total cases
99
Filed by the company
11
Filed against the company
88
Pending
7
Disposed
92
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 86 | 84 | 2 |
| High courts | 11 | 4 | 5 |
| Supreme Court | 2 | 0 | 0 |
Cases on record (5 of 99)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, North West, Delhi | Court case (CS (COMM.)) | Filed against the company by Ms Shah TC Distribution LLP | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary case) | Filed by the company against Dipna Pharmachem Limited | Disposed |
| District court, Chandigarh | Cheque dishonour complaint | Filed against the company by M/S Ind Swift Laboratories Ltd | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Crescent Pharma Limited | Pending |
| Bombay High Court | Commercial suit | Filed by the company against Crescent Pharma Limited | Pending |
To see the full case history of Umedica Laboratories Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Umedica Laboratories Private Limited was last rated by Crisil on 14 Oct 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 14 Oct 2020 |
To see the full credit ratings and regulatory alerts of Umedica Laboratories Private Limited, buy the company report.
MSME payment delays
Umedica Laboratories Private Limited has 4 MSME Form 1 returns on record between 2019 and 2024, listing 194 overdue payments to 44 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 44)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sensewell Calibration Ser | |||
| Care Forwarders | |||
| Priya Enterprise | |||
| Rinac Insulations Private Limited | |||
| Laqshya Logistics |
To see the full MSME payment records of Umedica Laboratories Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Umedica Laboratories Private Limited has a workforce of 869 employees on its EPFO records as of Jan 17, 2025, across 2 active EPFO establishments.
Employee count
869
Active EPFO establishments
2
Employee growth
12.13%
GST
Umedica Laboratories has 4 GST registrations: 3 active and 1 cancelled or inactive.
Total GSTINs
4
Active
3
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACU2966Q1ZS | Gujarat | Active | 01 Jul 2017 |
| 27AAACU2966Q1ZM | Maharashtra | Active | 01 Jul 2017 |
| 27AAACU2966Q3ZK | Maharashtra | Active | 28 May 2018 |
To see the full GST registrations and return filing status of Umedica Laboratories Private Limited, buy the company report.
Recent activity
Umedica Laboratories Private Limited has 7 board changes on record since 1982: 3 appointments and 4 cessations. The latest: Manish Umed Doshi ceased to be Director on 26 Feb 2025.
AGM
Umedica Laboratories Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 18 May 2020 via Charge ID 100346851 with Others was fully satisfied on 20 Jun 2025.
Charges
A charge registered on 14 May 2019 via Charge ID 100261751 with Others was fully satisfied on 02 Apr 2025.
Ceased
Manish Umed Doshi ceased to be Director.
Filing
Umedica Laboratories Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 132.69 Cr registered on 28 Oct 2021 with Charge ID 100497172 was modified on 23 Mar 2023.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 77.89 Cr registered on 01 Nov 2021 with Charge ID 100503919 was modified on 22 Nov 2022.
Charges
A charge with Sbicap Trustee Company Limited of Rs. 216.58 Cr registered on 28 Oct 2021 with Charge ID 100496986 was modified on 22 Nov 2022.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 15.00 Cr with Charge ID 100595703 was registered on 28 Jun 2022.
Charges
A charge registered on 19 Jun 2017 via Charge ID 100118649 with Others was fully satisfied on 02 May 2022.
Charges
A charge registered on 23 Mar 2018 via Charge ID 100206091 with Others was fully satisfied on 22 Mar 2022.
Charges
A charge registered on 19 Jun 2017 via Charge ID 100143813 with Others was fully satisfied on 22 Mar 2022.
52 earlier events are in the company report.
Frequently asked questions
Umedica Laboratories is an active private limited company based in Pardi, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 05 January 1982 (44+ years old) and is registered under CIN U24231GJ1982PTC141202.
Umedica Laboratories has 3 current directors:
- Manish Umed Doshi - Managing Director
- Rupesh Suryakant Kamdar - Director
- Vandana Manish Doshi - Director
The latest financial statements of Umedica Laboratories on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Umedica Laboratories is 24AAACU2966Q1ZS, registered in Gujarat. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 27AAACU2966Q1ZM (Maharashtra), 27AAACU2966Q3ZK (Maharashtra).
The CIN (Corporate Identification Number) of Umedica Laboratories is U24231GJ1982PTC141202. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Umedica Laboratories has 99 court cases on record: 11 filed by the company and 88 filed against it. 7 are pending. Most are in the district courts.
Umedica Laboratories was incorporated on 05 January 1982, making it 44+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Umedica Laboratories has 8 deals on record (4 funding rounds, 4 secondary share transfers), with disclosed funding of ₹56.01 Cr; the latest was in October 2022.
The peers of Umedica Laboratories by revenue are Troikaa Pharmaceuticals Limited, Tenshi Pharmaceuticals Private Limited, Blue Cross Laboratories Private Limited, Win-Medicare Private Limited, Franco-Indian Pharmaceuticals Private Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Manish Umed Doshi ceased to be Director on 26 Feb 2025. Rupesh Suryakant Kamdar ceased to be Additional Director on 29 Sep 2018. Rupesh Suryakant Kamdar was appointed as Director on 02 Aug 2018. Umedica Laboratories has 7 board changes on record in total.
Umedica Laboratories has 4 MSME Form 1 returns on record between 2019 and 2024, listing 194 overdue payments to 44 micro and small suppliers. The latest return was filed on 21 Jun 2024.
Umedica Laboratories can be reached through the website umedicalabs.com. Its registered office is in Pardi, Gujarat, India.